Peripheral
-
ViroMed receives approval for Phase II trial in the US for diabetic peripheral neuropathy
ViroMed announced that VM202-DPN, the company's proprietary DNA medicine for treatment of diabetic peripheral neuropathy, has received approval from the US FDA for a Phase II clinical trial.
Peripheral | 04 January 2012
-
ViroMed Receives Approval of Phase II Trial for Peripheral Artery Disease Drug
ViroMed has announced that VM202-PAD, a Deoxyribonucleic Acid (DNA) medicine for the treatment of Peripheral Artery Disease (PAD), has received approval from the US Food and Drug Administration (FDA) for a Phase II clinical trial. The trial will be p…
Peripheral | 24 July 2009
-
Vermillion, Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
Vermillion, Inc., formerly Ciphergen Biosystems, has announced the publication of research that details how a protein biomarker called beta-2 microglobulin may aid in the diagnosis of peripheral artery disease (PAD). The findings, which suggest be…
Peripheral | 01 September 2007
